Research Advance of Gene Mutation and Targeted Drug Therapy in Childhood Acute Myeloid Leukemia --Review

The clinical therapeutic regimen for acute myeloid leukemia (AML) is not significantly different between adults and children, which is mostly based on IA (idarubicin and cytosine arabinoside) induction chemotherapy. With the rapid development of sequencing technique, people's understandings tow...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 30; no. 2; p. 631
Main Authors DU, Cheng-Kan, Lu, Ying
Format Journal Article
LanguageChinese
Published China 01.04.2022
Subjects
targeted therapy
acute myeloid leukemia
children
gene mutation
Online AccessGet more information

Cover

More Information
Summary:The clinical therapeutic regimen for acute myeloid leukemia (AML) is not significantly different between adults and children, which is mostly based on IA (idarubicin and cytosine arabinoside) induction chemotherapy. With the rapid development of sequencing technique, people's understandings towards the molecular and biological abnormalities of AML are increasing, diverse AML gene mutation-based targeted drugs have been rapidly developed and applied. In this review, several commonly gene mutations in AML (such as FLT3, NPM1 and C/EBPA) was described, and the therapeutic effects and differences of targeted drugs that used in clinical treatment or had been reported (like tyrosine kinase inhibitor, IDH1 mutation inhibitor and epigenetic modification inhibitor) in child and adult AML patients were summrized.
ISSN:1009-2137
DOI:10.19746/j.cnki.issn.1009-2137.2022.02.052